Abstracts tagged "Biologic agents and tuberculosis"

Abstract Number: 2157 • 2014 ACR/ARHP Annual Meeting
Tuberculosis Reactivation Risk in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors: A Turkish Experience with Higher Mortality and Different Background Diseases
Bunyamin Kisacik¹, Omer Pamuk², Ahmet Mesut Onat³, B. Erer⁴, Gulen Hatemi⁵, Yesim Ozguler⁶, Yavuz Pehlivan⁷, Levent Kilic⁸, Ihsan Ertenli⁸, Meryem Can⁹, Haner Direskeneli⁹, Gökhan Keser¹⁰, Fahrettin Oksel¹⁰, Ediz Dalkilic¹¹, Sedat Yilmaz¹², Salih Pay¹³, Ayse Balkarli¹⁴, Veli Cobankara¹⁵, Gozde Yildirim Cetin¹⁶, Mehmet Sayarlioglu¹⁷, Ayse Cefle¹⁸, Ayten Yazici¹⁸, Ali Berkant Avci¹⁹, Ender Terzioglu²⁰, Suleyman Ozbek²¹, Servet Akar²² and Ahmet Gül²³, ¹Rheumatology, Gaziantep University, School of Medicine, Gaziantep, Turkey, ²Trakya Üniversitesi, edirne, Turkey, ³Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ⁶University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ⁷Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ⁸Hacettepe Üniversity, Ankara, Turkey, ⁹Marmara Üniversitesi, Ýstanbul, Turkey, ¹⁰Ege Üniversitesi, Ýzmir, Turkey, ¹¹Uludað Üniversitesi, Bursa, Turkey, ¹²GATA, ANKARA, Turkey, ¹³GATA, Ankara, Turkey, ¹⁴Pamukkale Üniversitesi, Denizli, Turkey, ¹⁵Denizli Üniversitesi, Denizli, Turkey, ¹⁶Deparment of Rheumatology, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, ¹⁷Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, ¹⁸Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, ¹⁹Antalya University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey, ²⁰School of Medicine, Akdeniz University, Antalya, Turkey, ²¹Cukurova Üniversitesi, Adana, Turkey, ²²Katip Çelebi Üniversitesi, Ýzmir, Turkey, ²³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose Tumor necrosis factor alpha inhibitors (anti-TNF) are a breakthrough for the treatment of inflammatory rheumatic diseases and tuberculosis (TB) is the prevailing and vitally…
Abstract Number: 1324 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Usefulness Of Interferon-Gamma Release Assays and Tuberculin Skin Test For Detection Of Latent Mycobacterium Tuberculosis Infection In Korean Rheumatic Patients With Biologic Agents
Jae-Hoon Kim¹, Soyoung Won², Chan-Bum Choi³, Yoon-Kyoung Sung⁴, Gwan Gyu Song¹ and Sang-Cheol Bae⁵, ¹Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: The screening for and treatment of latent tuberculosis infection (LTBI) before starting biologic agents is crucial to prevent reactivation and resultant serious infection. Several…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].